fluorodopa f 18 has been researched along with Cushing Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahonen, A; Schalin-Jäntti, C; Seppänen, M | 1 |
| Brousseau, M; Cahouet, A; Dubois, S; Girault, S; Illouz, F; Lacoeuille, F; Morel, O; Picquet, J; Rodien, P; Rohmer, V | 1 |
2 other study(ies) available for fluorodopa f 18 and Cushing Syndrome
| Article | Year |
|---|---|
18F-DOPA PET/CT but not 68Ga-DOTA-TOC PET/CT revealed the underlying cause of ectopic Cushing syndrome.
Topics: Cushing Syndrome; Dihydroxyphenylalanine; Humans; Male; Middle Aged; Multimodal Imaging; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
A Pulmonary adrenocorticotropin-secreting carcinoid tumor localized by 6-Fluoro-[18F]L-dihydroxyphenylalanine positron emission/computed tomography imaging in a patient with Cushing's syndrome.
Topics: Adolescent; Adrenocorticotropic Hormone; Carcinoid Tumor; Cushing Syndrome; Dihydroxyphenylalanine; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |